fda bpc-157 safety risks compounding Excellent news for us on the frontiers of medicine. Bringing back peptides to pharmacies is the long awaited expectation from this administration. I voted for this. In September 2023, the Biden FDA Briefing Document Pharmacy Compounding
Description
This lipolytic effect appears to be mediated through activation of 3-adrenergic receptors on adipocytes, which are G-protein coupled receptors that, when activated, stimulate adenylyl cyclase to increase intracellular cAMP levels
And thats the old school way to approach things
PMID 38673453
ZhaoMZhouYZhuBCWanMJJiangTTTanQQet al
